Spectranetics Cp T (SPNC) 19.46 $SPNC
Uptrend Call Working As Spectranetics Stock Rises 28.4% (SPNC)
Comtex SmarTrend(R) - Fri Jun 10, 1:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 28.41% as of today's recent price of $19.82.
SPNC: 19.46 (-0.36)
How are These Healthcare Stocks Faring? - Zimmer Biomet, Wright Medical, Spectranetics and Prestige Brands
PR Newswire - Fri Jun 03, 7:00AM CDT
In today's pre-market coverage, ActiveWallSt.com has these four Medical Appliances and Equipment stocks lined up for investors to review: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Wright Medical Group N.V. (NASDAQ: WMGI), The Spectranetics Corp. (NASDAQ: SPNC), and Prestige Brands Holdings Inc. (NYSE: PBH). Register now to access these stocks' trade alerts by clicking on the following link:
SPNC: 19.46 (-0.36), ZBH: 119.23 (-0.17), WMGI: 18.92 (-0.59), PBH: 52.77 (-0.84), WMGIZ: 1.40 (unch)
Shares of SPNC Up 26.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:55PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 26.27% as of today's recent price of $19.49.
SPNC: 19.46 (-0.36)
Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics' Stellarex drug-coated balloon at NCVH
GlobeNewswire - Wed Jun 01, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons annual conference in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 19.46 (-0.36)
SmarTrend Watching for Potential Pullback in Shares of Spectranetics After 5.77% Gain
Comtex SmarTrend(R) - Mon May 23, 4:32PM CDT
Spectranetics (NASDAQ:SPNC) traded in a range yesterday that spanned from a low of $16.56 to a high of $17.72. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $17.39 on volume of 534,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SPNC: 19.46 (-0.36)
Spectranetics to Present at the UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Chief Financial Officer Stacy McMahan will be presenting at the UBS Global Healthcare Conference on May 25, 2016, at the Grand Hyatt in New York City.
SPNC: 19.46 (-0.36)
Spectranetics reports 1Q loss
Automated Insights - Thu Apr 28, 6:28PM CDT
COLORADO SPRINGS, Colo. (AP) _ The Spectranetics Corp. (SPNC) on Thursday reported a loss of $17.3 million in its first quarter.
SPNC: 19.46 (-0.36)
Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million
GlobeNewswire - Thu Apr 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended March 31, 2016. Highlights of the quarter, all compared with the three months ended March 31, 2015, include:
SPNC: 19.46 (-0.36)
Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Wed Apr 27, 3:15AM CDT
Spectranetics (NASDAQ:SPNC) was downgraded from Buy to Hold at Craig-Hallum today. The stock closed yesterday at $16.91 on volume of 1.8 million shares, above average daily volume of 473,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 19.46 (-0.36)
12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics' Stellarex drug-coated balloon at Charing Cross
GlobeNewswire - Tue Apr 26, 5:30AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the ILLUMENATE Global Study at the Charing Cross Symposium in London, England. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 19.46 (-0.36)
Spectranetics to Host First Quarter 2016 Conference Call on April 28, 2016
GlobeNewswire - Thu Apr 07, 3:00PM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release first quarter 2016 financial results after the market close on Thursday, April 28, 2016. Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, April 28, 2016 to discuss results and provide a general business update.
SPNC: 19.46 (-0.36)
Spectranetics Names Udo Scheiner as Senior Vice President, International Operations
GlobeNewswire - Thu Mar 24, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Udo Scheiner has been named Senior Vice President, International Operations, effective March 23, 2016. In this role, Mr. Scheiner will report directly to Scott Drake, President and Chief Executive Officer, and will be based in Zurich, Switzerland.
SPNC: 19.46 (-0.36)
QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore
PR Newswire - Wed Feb 10, 8:07PM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, is pleased to provide an update in its ongoing litigation with AngioScore, Inc. ("ÄngioScore" (now owned by Spectranetics Corporation (NASDAQ: SPNC)).
SPNC: 19.46 (-0.36)
Spectranetics to Hold 2015 Fourth Quarter Financial Results Conference Call on February 25, 2016
GlobeNewswire - Tue Feb 09, 3:08PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2015 fourth quarter financial results after market close on Thursday, February 25, 2016. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 25 to discuss those results and to answer questions.
SPNC: 19.46 (-0.36)
Spectranetics passes US FDA 510(k) clearance for the cardiac life-saving technology Bridge Occlusion Balloon
M2 - Tue Feb 09, 5:27AM CST
Medical devices company Spectranetics Corporation (NasdaqGS:SPNC) revealed on Monday that it has received US Food and Drug Administration (FDA) Premarket Notification 510(k) clearance for its Bridge Occlusion Balloon for the safety, stability and procedural control in cardiac lead extraction procedures.
SPNC: 19.46 (-0.36)
US Market for Peripheral Vascular Devices and Accessories Report Suite 2016
M2 - Fri Jan 15, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5kqqx/us_market_for) has announced the addition of the "US Market for Peripheral Vascular Devices and Accessories Report Suite - 2016" report to their offering. Growth in the value of the U.S. market for peripheral vascular devices is being driven by the aging U.S. population, improving public awareness of peripheral arterial disease (PAD) and improvements in medical device technology. The transcatheter embolization device market is expected to be the fastest growing segment, increasing at a CAGR in the mid-to-high teens over the forecast period. The strong growth in this market will be a result of the increase in usage of radiolabeled and drug-eluting beads as well as the increasing penetration rate of detachable embolization coils. The U.S. market for peripheral vascular devices includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion (CTO) devices, embolic protection devices (EPDs), stent grafts, surgical grafts, thrombectomy devices, inferior vena cava filters (IVCFs), catheters, guidewires, introducer sheaths, vascular closure devices (VCDs) and transcatheter embolization devices. Many of these devices can be used for treating either coronary arterial disease or peripheral arterial disease (PAD). However, only devices used for peripheral procedures are included in this report. Key Topics Covered: 1 Overview 2 Research Methodology 3 U.S. Peripheral Vascular Device Market Overview 4 Procedure Numbers 5 Peripheral Vascular Stent Market 6 PTA Balloon Catheter Market 7 Atherectomy Device Market 8 Chronic Total Occlusion Device Market 9 Embolic Protection Device Market 10 Stent Graft Market 11 Surgical Graft Market 12 Thrombectomy Device Market 13 Inferior Vena Cava Filter Market 14 Diagnostic And Interventional Catheter Market 15 Diagnostic And Interventional Guidewire Market 16 Introducer Sheath Market Companies Mentioned - Medtronic - W.L. Gore - Cook Medical - Boston Scientific - C.R. Bard - Abbott Laboratories - Cardinal Health - Terumo - Endologix - Cardiovascular Systems Inc. - Sirtex - Maquet - BTG - St. Jude Medical - Spectranetics - Teleflex Medical - Advanced Vascular Dynamics - AngioSlide - Arstasis - C.R. Bard - Creagh Medical - EndoShape - HemCon Medical Technologies - Merit Medical Systems, Inc. - Morris Innovative, Inc. - Nantec Medical - Penumbra - Pfizer - Silk Road Medical - Teleflex Medical - Terumo - TriReme Medical - TZ Medical - Vascular Flow Technologies - W.L. Gore For more information visit http://www.researchandmarkets.com/research/l5...market_for
BSX: 23.02 (-0.30), SPNC: 19.46 (-0.36), ABT: 38.40 (-0.47), MDT: 85.70 (-0.08), CSII: 18.36 (+0.41), STJ: 77.35 (-0.72), MMSI: 19.12 (-0.52)
Spectranetics Shareholders and Former Employees Are Encouraged to Contact Court Appointed Lead Counsel Glancy Prongay & Murray in Securities Class Action
BusinessWire - Mon Jan 11, 11:32AM CST
Glancy Prongay & Murray LLP ("GPM" announces that it has been appointed Co-Lead Counsel in the securities class action against The Spectranetics Corporation ("Spectranetics" or the "Company" (NASDAQ: SPNC) and certain executive officers of the Company, currently pending in the United States District Court for the District of Colorado - Ellis v. The Spectranetics Corporation, et al., No. 15-cv-01857-KLM.
SPNC: 19.46 (-0.36)
Robbins Arroyo LLP is Investigating the Officers and Directors of The Spectranetics Corporation (SPNC) on Behalf of Shareholders
BusinessWire - Wed Dec 30, 2:09PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating claims that certain officers and directors of The Spectranetics Corporation (NASDAQGS: SPNC) violated the Securities Exchange Act of 1934 by making materially false and misleading statements about Spectranetics' business prospects. Spectranetics, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system.
SPNC: 19.46 (-0.36)
A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals, Spectranetics and Jinpan International
ACCESSWIRE - Tue Dec 29, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / December 29, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cobalt International Energy Inc. (NYSE: CIE), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Spectranetics Corp (NASDAQ: SPNC) and Jinpan International Ltd (NASDAQ: JST). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MACK: 6.32 (-0.24), SPNC: 19.46 (-0.36), JST: 5.94 (+0.07), CIE: 2.08 (-0.21)
Spectranetics to Present at the J.P. Morgan 34th Annual Healthcare Conference
GlobeNewswire - Mon Dec 28, 12:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the J.P. Morgan 34th Annual Healthcare Conference on January 13, 2016 in San Francisco.
SPNC: 19.46 (-0.36), JPM: 63.84 (-0.91)
Uptrend Call Working As Spectranetics Stock Rises 28.4% (SPNC)
Comtex SmarTrend(R) - Fri Jun 10, 1:00AM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 28.41% as of today's recent price of $19.82.
SPNC: 19.46 (-0.36)
How are These Healthcare Stocks Faring? - Zimmer Biomet, Wright Medical, Spectranetics and Prestige Brands
PR Newswire - Fri Jun 03, 7:00AM CDT
In today's pre-market coverage, ActiveWallSt.com has these four Medical Appliances and Equipment stocks lined up for investors to review: Zimmer Biomet Holdings Inc. (NYSE: ZBH), Wright Medical Group N.V. (NASDAQ: WMGI), The Spectranetics Corp. (NASDAQ: SPNC), and Prestige Brands Holdings Inc. (NYSE: PBH). Register now to access these stocks' trade alerts by clicking on the following link:
SPNC: 19.46 (-0.36), ZBH: 119.23 (-0.17), WMGI: 18.92 (-0.59), PBH: 52.77 (-0.84), WMGIZ: 1.40 (unch)
Shares of SPNC Up 26.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Jun 02, 1:55PM CDT
SmarTrend identified an Uptrend for Spectranetics (NASDAQ:SPNC) on March 4th, 2016 at $15.43. In approximately 3 months, Spectranetics has returned 26.27% as of today's recent price of $19.49.
SPNC: 19.46 (-0.36)
Second Interim Analysis on ILLUMENATE Global Study Presented on Spectranetics' Stellarex drug-coated balloon at NCVH
GlobeNewswire - Wed Jun 01, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Dr. Prakash Krishnan of Mount Sinai Medical Center, New York, NY presented the second interim analysis of 12-month data from the ILLUMENATE Global Study at the New Cardiovascular Horizons annual conference in New Orleans, Louisiana. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 19.46 (-0.36)
SmarTrend Watching for Potential Pullback in Shares of Spectranetics After 5.77% Gain
Comtex SmarTrend(R) - Mon May 23, 4:32PM CDT
Spectranetics (NASDAQ:SPNC) traded in a range yesterday that spanned from a low of $16.56 to a high of $17.72. Yesterday, the shares gained 5.8%, which took the trading range above the 3-day high of $17.39 on volume of 534,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SPNC: 19.46 (-0.36)
Spectranetics to Present at the UBS Global Healthcare Conference
GlobeNewswire - Wed May 11, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Chief Financial Officer Stacy McMahan will be presenting at the UBS Global Healthcare Conference on May 25, 2016, at the Grand Hyatt in New York City.
SPNC: 19.46 (-0.36)
Spectranetics reports 1Q loss
Automated Insights - Thu Apr 28, 6:28PM CDT
COLORADO SPRINGS, Colo. (AP) _ The Spectranetics Corp. (SPNC) on Thursday reported a loss of $17.3 million in its first quarter.
SPNC: 19.46 (-0.36)
Spectranetics Achieves First Quarter 2016 Revenue of $62.9 million
GlobeNewswire - Thu Apr 28, 3:01PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today reported financial results for the three months ended March 31, 2016. Highlights of the quarter, all compared with the three months ended March 31, 2015, include:
SPNC: 19.46 (-0.36)
Downgrade Alert for Spectranetics (SPNC)
Comtex SmarTrend(R) - Wed Apr 27, 3:15AM CDT
Spectranetics (NASDAQ:SPNC) was downgraded from Buy to Hold at Craig-Hallum today. The stock closed yesterday at $16.91 on volume of 1.8 million shares, above average daily volume of 473,000. The Spectranetics Corporation develops, manufactures, markets, and distributes its technology for interventional cardiovascular therapy. The Company's CVX-300 excimer laser system is used in applications such as coronary angioplasty and the removal of pacemaker leads. Spectranetics is also developing other applica- tions in restenosis stents and peripheral vascular applications.
SPNC: 19.46 (-0.36)
12-Month Interim ILLUMENATE Global Study Data Presented on Spectranetics' Stellarex drug-coated balloon at Charing Cross
GlobeNewswire - Tue Apr 26, 5:30AM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Professor Thomas Zeller presented 12-month interim data from the ILLUMENATE Global Study at the Charing Cross Symposium in London, England. The ILLUMENATE Global Study is a prospective, multicenter, single-arm study designed to assess the clinical performance of the Stellarex(TM) drug-coated balloon (DCB) in the superficial femoral and popliteal arteries.
SPNC: 19.46 (-0.36)
Spectranetics to Host First Quarter 2016 Conference Call on April 28, 2016
GlobeNewswire - Thu Apr 07, 3:00PM CDT
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release first quarter 2016 financial results after the market close on Thursday, April 28, 2016. Company management will host a conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, April 28, 2016 to discuss results and provide a general business update.
SPNC: 19.46 (-0.36)
Spectranetics Names Udo Scheiner as Senior Vice President, International Operations
GlobeNewswire - Thu Mar 24, 3:00PM CDT
The Spectranetics Corporation (NASDAQ:SPNC) today announced that Udo Scheiner has been named Senior Vice President, International Operations, effective March 23, 2016. In this role, Mr. Scheiner will report directly to Scott Drake, President and Chief Executive Officer, and will be based in Zurich, Switzerland.
SPNC: 19.46 (-0.36)
QT Vascular Announces Another Positive Outcome in Litigation with Spectranetics/Angioscore
PR Newswire - Wed Feb 10, 8:07PM CST
QT Vascular Ltd., together with its subsidiaries (the "Company" or "QT Vascular", and together with its subsidiaries, the "Group"
, is pleased to provide an update in its ongoing litigation with AngioScore, Inc. ("ÄngioScore" (now owned by Spectranetics Corporation (NASDAQ: SPNC)). SPNC: 19.46 (-0.36)
Spectranetics to Hold 2015 Fourth Quarter Financial Results Conference Call on February 25, 2016
GlobeNewswire - Tue Feb 09, 3:08PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that the Company will release 2015 fourth quarter financial results after market close on Thursday, February 25, 2016. Company management will host an investment-community conference call beginning at 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on Thursday, February 25 to discuss those results and to answer questions.
SPNC: 19.46 (-0.36)
Spectranetics passes US FDA 510(k) clearance for the cardiac life-saving technology Bridge Occlusion Balloon
M2 - Tue Feb 09, 5:27AM CST
Medical devices company Spectranetics Corporation (NasdaqGS:SPNC) revealed on Monday that it has received US Food and Drug Administration (FDA) Premarket Notification 510(k) clearance for its Bridge Occlusion Balloon for the safety, stability and procedural control in cardiac lead extraction procedures.
SPNC: 19.46 (-0.36)
US Market for Peripheral Vascular Devices and Accessories Report Suite 2016
M2 - Fri Jan 15, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/l5kqqx/us_market_for) has announced the addition of the "US Market for Peripheral Vascular Devices and Accessories Report Suite - 2016" report to their offering. Growth in the value of the U.S. market for peripheral vascular devices is being driven by the aging U.S. population, improving public awareness of peripheral arterial disease (PAD) and improvements in medical device technology. The transcatheter embolization device market is expected to be the fastest growing segment, increasing at a CAGR in the mid-to-high teens over the forecast period. The strong growth in this market will be a result of the increase in usage of radiolabeled and drug-eluting beads as well as the increasing penetration rate of detachable embolization coils. The U.S. market for peripheral vascular devices includes stents, percutaneous transluminal angioplasty (PTA) balloon catheters, atherectomy devices, chronic total occlusion (CTO) devices, embolic protection devices (EPDs), stent grafts, surgical grafts, thrombectomy devices, inferior vena cava filters (IVCFs), catheters, guidewires, introducer sheaths, vascular closure devices (VCDs) and transcatheter embolization devices. Many of these devices can be used for treating either coronary arterial disease or peripheral arterial disease (PAD). However, only devices used for peripheral procedures are included in this report. Key Topics Covered: 1 Overview 2 Research Methodology 3 U.S. Peripheral Vascular Device Market Overview 4 Procedure Numbers 5 Peripheral Vascular Stent Market 6 PTA Balloon Catheter Market 7 Atherectomy Device Market 8 Chronic Total Occlusion Device Market 9 Embolic Protection Device Market 10 Stent Graft Market 11 Surgical Graft Market 12 Thrombectomy Device Market 13 Inferior Vena Cava Filter Market 14 Diagnostic And Interventional Catheter Market 15 Diagnostic And Interventional Guidewire Market 16 Introducer Sheath Market Companies Mentioned - Medtronic - W.L. Gore - Cook Medical - Boston Scientific - C.R. Bard - Abbott Laboratories - Cardinal Health - Terumo - Endologix - Cardiovascular Systems Inc. - Sirtex - Maquet - BTG - St. Jude Medical - Spectranetics - Teleflex Medical - Advanced Vascular Dynamics - AngioSlide - Arstasis - C.R. Bard - Creagh Medical - EndoShape - HemCon Medical Technologies - Merit Medical Systems, Inc. - Morris Innovative, Inc. - Nantec Medical - Penumbra - Pfizer - Silk Road Medical - Teleflex Medical - Terumo - TriReme Medical - TZ Medical - Vascular Flow Technologies - W.L. Gore For more information visit http://www.researchandmarkets.com/research/l5...market_for
BSX: 23.02 (-0.30), SPNC: 19.46 (-0.36), ABT: 38.40 (-0.47), MDT: 85.70 (-0.08), CSII: 18.36 (+0.41), STJ: 77.35 (-0.72), MMSI: 19.12 (-0.52)
Spectranetics Shareholders and Former Employees Are Encouraged to Contact Court Appointed Lead Counsel Glancy Prongay & Murray in Securities Class Action
BusinessWire - Mon Jan 11, 11:32AM CST
Glancy Prongay & Murray LLP ("GPM"
announces that it has been appointed Co-Lead Counsel in the securities class action against The Spectranetics Corporation ("Spectranetics" or the "Company" (NASDAQ: SPNC) and certain executive officers of the Company, currently pending in the United States District Court for the District of Colorado - Ellis v. The Spectranetics Corporation, et al., No. 15-cv-01857-KLM. SPNC: 19.46 (-0.36)
Robbins Arroyo LLP is Investigating the Officers and Directors of The Spectranetics Corporation (SPNC) on Behalf of Shareholders
BusinessWire - Wed Dec 30, 2:09PM CST
Shareholder rights law firm Robbins Arroyo LLP is investigating claims that certain officers and directors of The Spectranetics Corporation (NASDAQGS: SPNC) violated the Securities Exchange Act of 1934 by making materially false and misleading statements about Spectranetics' business prospects. Spectranetics, together with its subsidiaries, develops, manufactures, markets, and distributes single-use medical devices used in minimally invasive procedures in the cardiovascular system.
SPNC: 19.46 (-0.36)
A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals, Spectranetics and Jinpan International
ACCESSWIRE - Tue Dec 29, 7:30AM CST
NEW YORK, NY / ACCESSWIRE / December 29, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Cobalt International Energy Inc. (NYSE: CIE), Merrimack Pharmaceuticals Inc. (NASDAQ: MACK), Spectranetics Corp (NASDAQ: SPNC) and Jinpan International Ltd (NASDAQ: JST). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
MACK: 6.32 (-0.24), SPNC: 19.46 (-0.36), JST: 5.94 (+0.07), CIE: 2.08 (-0.21)
Spectranetics to Present at the J.P. Morgan 34th Annual Healthcare Conference
GlobeNewswire - Mon Dec 28, 12:05PM CST
The Spectranetics Corporation (Nasdaq:SPNC) today announced that its management will be presenting at the J.P. Morgan 34th Annual Healthcare Conference on January 13, 2016 in San Francisco.
SPNC: 19.46 (-0.36), JPM: 63.84 (-0.91)
